Sodium-glucose co-transporter-2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes: systematic review and meta-analysis.

ABSTRACT:

Objective

To examine cardiovascular and kidney benefits and harms of sodium-glucose co-transporter-2 (SGLT-2) inhibitors stratified by risk in adults with chronic kidney disease regardless of diabetes status.

Design

Systematic review and meta-analysis.

Data sources

Ovid Medline, Embase, and Cochrane Central from database inception to 15 June 2024.

Eligibility criteria for selecting studies

Randomised controlled trials that compared SGLT-2 inhibitors with placebo or standard care with no SGLT-2 inhibitors in adults with chronic kidney disease with a follow-up duration of ≥12 weeks were eligible. Secondary analyses based on subpopulations from randomised controlled trials and publications not in English language were excluded.

Data synthesis

Random effects

SUBMITTER: Zou X 

PROVIDER: S-EPMC11579537 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature